Savarirayan, R., Muslimova, E., Bergua, J., Arundel, P., Salles, J., Saraff, V., . . . Rogoff, D. O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study. Elsevier.
Chicago Style (17th ed.) CitationSavarirayan, Ravi, et al. O13: Oral Infigratinib for Children with Achondroplasia: Month 18 Results from the PROPEL 2 Study. Elsevier.
MLA (9th ed.) CitationSavarirayan, Ravi, et al. O13: Oral Infigratinib for Children with Achondroplasia: Month 18 Results from the PROPEL 2 Study. Elsevier.
Warning: These citations may not always be 100% accurate.